Protocol for a multicentre randomised controlled trial examining the effects of temporarily pausing Bruton tyrosine kinase inhibitor therapy to coincide with SARS-CoV-2 vaccination... by Abhishek Abhishek, Jonathan A Cook, Helen M Parry, Anne Francis, Lelia Duley, Vicki S Barber, Paul Moss, Nicholas Peckham

Get full text

The need for evidence-based, outcome-focused medical imaging research for cancer management by Jiazheng Wang, Richard L. Hesketh, John C. Gore, Kevin M. Brindle

“…We argue there remain compelling needs for better designs of clinical trials, imaging protocol standards, quantification methods, efficient translation pathways and patient engagement.…”
Get full text

Non-pharmacological interventions for the reduction and maintenance of blood pressure in people with prehypertension: a systematic review protocol by Paul Rutter, Andrew Clegg, Valerio Benedetto, Caroline Watkins, Nefyn Williams, Joseph Spencer, Lucy Hives, Emma P Bray, Cath Harris, Rachel F Georgiou, Nafisa Iqbal

“…The databases/trial registries that will be searched to identify relevant randomised controlled trials (RCTs) and economic evaluations include Medline, EMBASE, CINAHL, PsycINFO, CENTRAL, the WHO International Clinical Trials Registry Platform, ClinicalTrials.gov, Cochrane Library, Scopus and the International HTA Database. …”
Get full text

The Role of Lactobacillus reuteri DSMZ17648 for Helicobacter pylori eradication therapy (Review of literature and advisory council resolution, February 28, 2018) by V. T. Ivashkin, O. P. Alekseyeva, A. Yu. Baranovsky, Ye. K. Baranskaya, Ye. V. Beloborodova, T. A. Kolesov, N. V. Korochanskaya, K. . Lang, T. L. Lapina, I. V. Mayev, M. V. Mokshina, D. L. Nepomnyashchy, Ye. V. Onuchina, R. G. Sayfutdinov, T. H. Sviridova, V. I. Simanenkov, A. V. Tkachev, A. S. Trukhmanov, L. P. Faizova, I. B. Khlynov, O. B. Khlynova, A. A. Sheptulin

“…Potential of PylopassTM combination to various H. pylori eradication therapy modes is a subject offutnet multicenter randomized clinical trials for assessment of optimal combination to antibiotic drugs, treatment duration and adverse effect rates. …”
Get full text

Hepatocellular carcinoma: signaling pathways and therapeutic advances by Jiaojiao Zheng, Siying Wang, Lei Xia, Zhen Sun, Kui Ming Chan, René Bernards, Wenxin Qin, Jinhong Chen, Qiang Xia, Haojie Jin

“…Here, we provide here a comprehensive review of cellular signaling pathways, their therapeutic potential, evidence derived from late-stage clinical trials in HCC and discuss the concepts underlying earlier clinical trials, biomarker identification, and the development of more effective therapeutics for HCC.…”
Get full text

Therapeutics in paediatric genetic diseases: current and future landscape by Ai Ling Koh, Saumya Shekhar Jamuar

“…Specifically, gene therapy has been shown to be effective in various clinical trials, and indeed, these trials have led to regulatory approvals, paving the way for gene therapies for other types of PGDs. …”
Get full text

Efficacy of the herbal preparation STW 5 in multi-target therapy of functional dyspepsia by A. A. Sheptulin, V. O. Kaybysheva

“…Mechanism of action includes effect on motility of the stomach and intestine, visceral sensitivity along with anti-inflammatory and cytoprotective effects. Controlled clinical trials have confirmed high efficacy of Iberogast® at treatment of FD (including pediatric practice) as well as good tolerability of the drug.Conclusion. …”
Get full text

Understanding cancer predisposition in Singapore: what’s next by Jianbang Chiang, Tarryn Shaw, Joanne Ngeow

“…These include the potential for finding unexpected germline variants through somatic tumour testing, optimal risk management of patients with hereditary conditions involving moderate-penetrance genes, role of polygenic risk score in an under-represented Asian population, management of variants of uncertain significance, clinical trials in patients with germline pathogenic variants and technology in genetic counselling. …”
Get full text

“Lost in translation?” Animal research in the era of precision medicine by Hamideh Frühwein, Norbert W. Paul

“…Abstract Preclinical animal research has long been a cornerstone in evaluating the efficacy, toxicity, and safety of potential drug treatments before they proceed to human clinical trials. However, given the intricate nature of human physiology and the complexities of diseases such as cancer, this paper critically examines the role of animal experimentation in translational research, both from epistemological and ethical viewpoints. …”
Get full text

Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis by D. V. Garbuzenko

“…Given a lack of approved antifibrotic therapies in NASH, several drugs have nevertheless demonstrated an adequate efficacy and safety in phase 3 clinical trials, also in compensated cirrhosis, which allows their practical validation in phase 4.Conclusion. …”
Get full text

A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment o... by Yan Gong, James Rogers, Christian Friedrich, Sanjay Patel, Alexander Staab, Jorge Luiz Gross, Daniel Polhamus, William Gillespie, Brigitta Ursula Monz, Silke Retlich

“…Comparison of two oral dipeptidyl peptidase (DPP)-4 inhibitors, sitagliptin and linagliptin, for type 2 diabetes mellitus (T2DM) treatment was used as an example.Design Systematic review with MBMA.Data sources MEDLINE, EMBASE, http://www.ClinicalTrials.gov, Cochrane review of DPP-4 inhibitors for T2DM, sitagliptin trials on Food and Drug Administration website to December 2011 and linagliptin data from the manufacturer.Eligibility criteria for selecting studies Double-blind, randomised controlled clinical trials, ≥12 weeks’ duration, that analysed sitagliptin or linagliptin efficacies as changes in glycated haemoglobin (HbA1c) levels, in adults with T2DM and HbA1c >7%, irrespective of background medication.Model development and application A Bayesian model was fitted (Markov Chain Monte Carlo method). …”
Get full text

From bench to bedside: Developing CRISPR/Cas-based therapy for ocular diseases by Qing Zhao, Linxin Wei, Youxin Chen

“…This review summarizes the application strategies and delivery methods of CRISPR/Cas, discusses recent progress in CRISPR/Cas-based disease models and therapies, and provides an overview of the landscape of clinical trials. Current obstacles and future directions regarding the bench-to-bedside transition are also discussed.…”
Get full text

Randomised controlled trial of topical kanuka honey for the treatment of rosacea by James Fingleton, Mark Weatherall, Richard Beasley, Irene Braithwaite, Janwillem Kocks, Mark Holliday, Andrew Corin, Colin Helm, Davitt Sheahan, Barney Montgomery, Judith Riley, Anna Hunt, Christopher Tofield

“…The VAS-CS at week 2 was 9.1 (95% CI 3.5 to 14.7), p=0.002, and at week 8 was 12.3 (95% CI 5.7 to 18.9)¸ p<0.001 for Honevo compared to control.Conclusions Honevo is an effective treatment for rosacea.Trial registration number This trial was registered in the Australian and New Zealand Clinical Trials Registry ACTRN12614000004662.…”
Get full text

Artificial intelligence-based video monitoring of movement disorders in the elderly: a review on current and future landscapes by Kye Won Park, Maryam S Mirian, Martin J McKeown

“…The AI-based video monitoring systems offer improved efficiency and objectivity in remote patient monitoring, enabling real-time analysis of data, more uniform outcomes and augmented support for clinical trials. However, challenges, such as video quality, privacy compliance and noisy training labels, during development need to be addressed. …”
Get full text

Current and future therapeutic options for chronic hepatitis D virus infection by Mariantonietta Pisaturo, Antonio Russo, Pierantonio Grimaldi, Salvatore Martini, Nicola Coppola

“…PegIFNα, for which there are more data, appears to be an excellent combination regimen, if not contraindicated, both for Bulevirtide (BLV), data supported by important clinical trials and real-world studies, and probably for lonarfanib, although in the latter case the results are not yet definitive as the studies are fewer. …”
Get full text

Effectiveness of Prolotherapy for Chronic Musculoskeletal Conditions by Saurabh Agarwal, Abhishek Nagaich, Nikhil Jain, Arvind Kumar Shah

“…The efficacy of prolotherapy for different musculoskeletal conditions with different injections is different, and the precise mechanism of prolotherapy effect is still not clear, so further studies and clinical trials are recommended.…”
Get full text

Inflammatory Bowel Disease and Statins by V. V. Genkel, I. I. Shaposhnik

“…However, well-planned randomised clinical trials are needed to evaluate the effects of statins in IBD.…”
Get full text

Linezolid and serotonin syndrome by Haytham A. Wali

“…Assessments of the pharmacological mechanisms, large-scale clinical trials, and cohort studies are essential to elucidate risk factors and outcomes. …”
Get full text

Belzutifan for the treatment of renal cell carcinoma by Xiancheng Wu, David Lazris, Risa Wong, Scott S. Tykodi

“…Belzutifan has demonstrated activity in clinical trials as a front- and later-line therapy, and in combination with tyrosine kinase inhibitors. …”
Get full text

Intestinal microbiome as effective regulator of enteral and central nervous system activity by V. T. Ivashkin, K. V. Ivashkin

“…Accumulated data change the current concept on human microbiome and its potential, however further clinical trials required.…”
Get full text